Vanderbilt Center for Neuroscience Drug Discovery Archives
Investigational new drug for Alzheimer’s scheduled for first study in humans
Dec. 27, 2016—Vanderbilt University scientists have received notification from the U.S. Food and Drug Administration that testing in humans may proceed for an investigational new drug for Alzheimer's disease after more than 10 years of research by scientists at Vanderbilt University and Vanderbilt University Medical Center.
Researchers eye potential schizophrenia ‘switch’
Sep. 15, 2016—Researchers at Vanderbilt University Medical Center have discovered a key mechanism that explains how compounds they’re developing can suppress schizophrenia-like symptoms without side effects in mice.
Foundation’s support speeds search for new schizophrenia drugs at Vanderbilt
Aug. 15, 2016—Research in the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) aimed at developing innovative new treatments for schizophrenia just received a powerful assist from The William K. Warren Foundation.
Putting schizophrenia to bed
Mar. 21, 2016—A new compound developed at Vanderbilt treats multiple symptoms of schizophrenia in an animal model, without causing sedation.
Study reveals possible ‘dimmer switch’ drug for Rett syndrome
Mar. 3, 2016—Researchers at Vanderbilt University Medical Center have relieved symptoms in a mouse model of Rett syndrome with a drug-like compound that works like the dimmer switch in an electrical circuit.
Compound developed at VUMC may delay Huntington’s disease
Oct. 29, 2015—A compound developed by researchers at Vanderbilt University can improve early symptoms and delay progression of Huntington’s disease in a mouse model of the neurodegenerative disorder.
Grant enhances mental illness drug research efforts
Jul. 16, 2015—Research at Vanderbilt University Medical Center aimed at developing potential new treatments for major depressive disorder, general anxiety disorder and post-traumatic stress disorder got a big boost this week from The William K. Warren Foundation of Tulsa, Oklahoma.
Findings reveal new target in quest to ease schizophrenia
May. 7, 2015—Vanderbilt University researchers have uncovered a surprising finding that could lead to the development of new, more effective therapies for schizophrenia, which affects more than 2 million Americans.
Grant spurs schizophrenia research
Feb. 12, 2015—Vanderbilt University is partnering with the William K. Warren Foundation of Tulsa, Oklahoma, on research aimed at improving the treatment of schizophrenia and other forms of serious mental illness.
Schizophrenia ‘switches’ discovered
Sep. 12, 2014—Drugs developed at Vanderbilt could provide a new way to treat schizophrenia in a personalized way.
‘Missing link’ may spur new brain disorder drugs
Mar. 13, 2014—Researchers at the Scripps Research Institute in San Diego and Vanderbilt University have discovered a “missing link” in the structure of a transmembrane receptor that could lead to new treatments for autism, schizophrenia, Parkinson’s disease and Alzheimer’s disease.
Newsmakers: Vanderbilt’s teaching, research and patient care efforts are making an impact
May. 6, 2013—These stories from the past year show how Vanderbilt is making an impact, on campus and in the world.
